Clovis Oncology (CLVSQ) 10-Q2017 Q2 Quarterly report

Filed: 3 Aug 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: art, average, BICR, blinded, camsylate, central, CHMP, cleared, composition, constellation, counterpart, Department, dosage, dosing, endpoint, extension, favorable, forthcoming, found, Grossmann, high, imposition, independent, inventive, joint, Justice, key, lack, likewise, LLP, modification, novelty, overcompensated, PFS, placebo, platinum, polymorph, polymorphic, preliminarily, protection, repleading, resolve, Restoration, salt, sNDA, Solak, strength, supplementary, survival, unexpected, Verified, weighted, wrongful

Removed: addressing, assert, conclusion, cooperating, demurrer, denied, designation, discovery, entity, Grossman, Kimbro, memorandum, moot, Moran, moved, Northern, operative, prejudice, presentation, Ralph, remand, removed, Rocco, ruling, Steve, stipulated, supporting

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CLVSQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing


		Exhibit 21.1
List of Subsidiaries of Clovis Oncology, Inc.

Name:		Jurisdiction of Organization:
Clovis Oncology UK Limited		United Kingdom
Clovis Oncology Italy Srl		Italy
Clovis Oncology IT Srl		Italy
Clovis Oncology Switzerland GmbH		Switzerland
Clovis Oncology France SAS		France
Clovis Oncology Spain SL		Spain
Clovis Oncology Germany GmbH		Germany
Clovis Oncology Denmark ApS		Denmark

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.